Sugi Predict

Sugi Predict / Compounds / SCHEMBL3140886

SCHEMBL3140886

SCHEMBL3140886

Cc1c(Br)ccc2ccc(=O)[nH]c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 5/20 0.58
▸ CA9 Q16790 5/20 0.58
▸ CA1 P00915 1/20 0.36
▸ CA3 P07451 1/20 0.36
▸ CA4 P22748 1/20 0.36
▸ CA6 P23280 1/20 0.36
▸ CA5A P35218 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA13 Q8N1Q1 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ CA5B Q9Y2D0 1/20 0.36
▸ HCAR1 Q9BXC0 5/20 0.36
▸ GRIN2D O15399 1/20 0.33
▸ GRIN3B O60391 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2A Q12879 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ GRIN2C Q14957 1/20 0.33
▸ GRIN3A Q8TCU5 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12569582 0.79 CA12 (0.47) CA12CA9CA1CA3CA4
SCHEMBL14726207 0.76 KDM4E (0.56) CA12CA9CA1CA3CA4
SCHEMBL1438126 0.76 CA12 (0.44) CA12CA9CA1CA3CA4
SCHEMBL2819163 0.76 CA12 (0.58) CA12CA9CA1CA3CA4
SCHEMBL15448608 0.76 CA12 (0.58) CA12CA9CA1CA3CA4
SCHEMBL21631578 0.76 CA12 (0.58) CA12CA9CA1CA3CA4
SCHEMBL29970624 0.76 CA12 (0.58) CA12CA9CA1CA3CA4
SCHEMBL4573974 0.76 CA12 (0.58) CA12CA9CA1CA3CA4
SCHEMBL4589419 0.76 CA12 (0.53) CA12CA9CA1CA3CA4
Hydrochloric Acid SCHEMBL9431750 0.74 KDM4E (0.54) CA12CA9CA1CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 — — US disclosed
US-20240166661-A1 Spiropiperidine Derivatives CEPHALON LLC 2024-05-23 — — US disclosed
US-11878982-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2024-01-23 — — US disclosed
US-20210284651-A1 Spiropiperidine Derivatives CEPHALON LLC 2021-09-16 — — US disclosed
US-11046707-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2021-06-29 — — US disclosed
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON LLC 2020-01-30 — — US disclosed
EP-3554637-A1 SPIROPIPERIDINE DERIVATIVES 89Bio Ltd. (IL) 2019-10-23 — — EP disclosed
US-10160726-B2 Quinolone derivatives as antibacterials NOVARTIS AG (CH) 2018-12-25 — — US disclosed
WO-2018112204-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2018-06-21 — — WO disclosed
US-20170217897-A1 QUINOLONE DERIVATIVES AS ANTIBACTERIALS WUXI APPTEC (CN) 2017-08-03 — — US disclosed
US-20100048544-A1 PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS GLAXO GROUP LIMITED (GB) 2010-02-25 — — US disclosed
EP-1954697-B1 PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2010-02-24 — — EP disclosed
EP-2136807-A1 PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS Glaxo Group Limited (GB) 2009-12-30 — — EP disclosed
CN-101346379-A Per-cyclic tricyclic compounds useful as antibacterial agents GLAXO GROUP LTD (GB) 2009-01-14 — — CN disclosed
US-20080280892-A1 Compounds GLAXO GROUP LIMITED (GB) 2008-11-13 — — US disclosed
WO-2008125594-A1 PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS GLAXO GROUP LIMITED (GB) 2008-10-23 — — WO disclosed
EP-1980251-A1 Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis GLAXO GROUP LIMITED (GB) 2008-10-15 — — EP disclosed
US-20080221110-A1 Compounds GLAXO GROUP LIMITED (GB) 2008-09-11 — — US disclosed
EP-1954697-A2 PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2008-08-13 — — EP disclosed
WO-2007081597-A2 PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217897-A1 QUINOLONE DERIVATIVES AS ANTIBACTERIALS TOP1, NQO2, TOP2A CA12 4049/4885CA9 1431/4885CA1 3911/4885
US-11878982-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 CA12 4658/4885CA9 2790/4885CA1 3994/4885
US-20080221110-A1 Compounds NRDC, NISCH, MRPL21 CA12 2476/4885CA9 1182/4885CA1 4162/4885
US-20210284651-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 CA12 4658/4885CA9 2790/4885CA1 3994/4885
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES FASN, FADS2, SCD5 CA12 4658/4885CA9 2790/4885CA1 3994/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 CA12 4658/4885CA9 2790/4885CA1 3994/4885
US-20240166661-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 CA12 4658/4885CA9 2790/4885CA1 3994/4885
US-10160726-B2 Quinolone derivatives as antibacterials TOP1, NQO2, TOP2A CA12 4049/4885CA9 1431/4885CA1 3911/4885
US-20100048544-A1 PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS NQO2, MT-ND1, SDHB CA12 4783/4885CA9 4146/4885CA1 4811/4885
US-20080280892-A1 Compounds NRDC, NACA, NAA50 CA12 2814/4885CA9 1159/4885CA1 3956/4885
US-11046707-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 CA12 4658/4885CA9 2790/4885CA1 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.